In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The $100 Million IND

Executive Summary

An extraordinary series of high-value IND-stage deals could help to solve what has always been the intractable problem for biotechs: how to fund late-stage product development and simultaneously re-fill the early-stage pipeline. Still, it will be the rare biotech that can pull off this strategy--which requires INDs in the hottest areas of pharmaceutical development.
Advertisement

Related Content

IND Over POC: The New Sweet Spot For Biopharma Dealmaking
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
In HCV, Protease Race Heats Up with Combo Therapy Looming
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire
Deal Statistics Quarterly, Q3 2006
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma
The Large Molecule Future
Novartis's Research Experiment
Theravance: Having Cake and Eating It

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel